Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Genital herpes infections and their related complications lead to billions of dollars in health care expenditures and productivity losses globally, say researchers who calculated the first-ever global estimates of the economic costs of these conditions.

Cold sore

Calculating costs in 2016 international dollars (I$), the researchers detailed the associated economic cost estimates for genital herpes simplex virus (HSV) infections in 194 countries. They estimated the global economic burden of genital HSV-2 and HSV-1 infections to be I$35.3 billion in 2016, with genital HSV-2 accounting for I$31.2 billion of this burden, HSV-1 contributing I$4.0 billion. The Americas and Western Pacific regions accounted for almost two-thirds of the global burden (I$20·8 billion).

The substantial economic burden was largely driven by the recurrent nature of genital HSV-2 infections. Even with conservative estimates of one symptomatic episode per year per individual, the global costs of genital HSV-2 infections were estimated at I$16.5 billion.

Published in the journal BMC Global and Public Health, the paper, Estimated Global and Regional Economic Burden of Genital Herpes Simplex Virus Infection among 15-49 Years-olds in 2016, calls for greater investment in prevention of herpes transmission, including concerted efforts to develop effective vaccines against this common virus.

Corresponding author Prof Nathorn Chaiyakunapruk, College of Pharmacy, University of Utah Health, Health Economist Puttarin Kulchaitanaroaj, MORU in Bangkok, and their colleagues performed the research in collaboration with the World Health Organization (WHO) and other academic institutions.

Herpes is caused by infection with one of two types of the herpes simplex virus (HSV). Around two thirds of world’s population (67%) aged 0-49 have HSV-1, according to the latest published statistics. It is mostly acquired in childhood, spreads by oral contact, and causes infections in or around the mouth (oral herpes or cold sores). Adults can acquire genital HSV-1 infection through sexual contact if they were not infected during childhood. Type 2 spreads by sexual contact and causes genital herpes. Approximately 13% of the world’s population aged 15–49 years are living with HSV-2 infection.

In addition to sores and blisters, HSV can cause other more serious complications requiring healthcare attention, including a rare chance of mother to child transmission during childbirth, and increased risk of HIV infection.

Read the full article on the BMC Global and Public Health site: https://bmcglobalpublichealth.biomedcentral.com/articles/10.1186/s44263-024-00053-6

Similar stories

Building the world's evidence base to tackle drug-resistant tuberculosis

£10 million international research programme launches across India, Kazakhstan, Mozambique, South Africa and Vietnam.

A New Layer of Control for a Decades-Old Leukemia Drug

How cells respond to the leukemia drug 6-thioguanine still holds surprises: A new study, led jointly by researchers from CeMM and the University of Oxford identifies NUDT5 as an unexpected regulator of drug sensitivity and reveals that its role has nothing to do with its enzymatic activity.

Team ATLAS sets out strategy to investigate cancer avoidance as part of Cancer Grand Challenges

A new position paper from team ATLAS sets out plans to build a cancer antibody atlas to investigate why some people avoid cancer, while others develop disease.

Decades old puzzle solved as scientists uncover cause of inflammatory bowel disease

Scientists have identified the missing link between a long-known genetic signal in inflammatory bowel disease and a damaging immune response that switches off the body’s natural control of inflammation - opening the door to faster diagnosis and targeted treatment.

Oxford Bundibugyo ebolavirus vaccine candidate receives CEPI backing

The Coalition for Epidemic Preparedness Innovations (CEPI) has announced today that it will urgently accelerate the development of three investigational vaccines targeting the Bundibugyo ebolavirus that has caused a rapidly spreading epidemic in the Democratic Republic of the Congo (DRC) and neighbouring Uganda, including one being developed by the Oxford Vaccine Group at the University of Oxford.

New study improves early detection of life threatening infection in children across South and South East Asia

A new study published in Nature Medicine suggests that simple, low-cost tools could help health workers identify children at risk of life-threatening infection earlier, improving access to urgent care in across South and South East Asia.